Report for Q3 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 600535 ·
6ix is reading this filing.
View original source (Shanghai Stock Exchange)Tasly Pharmaceutical Group Co. Ltd. on 6ix
Earlier from Tasly Pharmaceutical
- (600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Obtaining Drug Registration Certificate by Subsidiary
- (600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Obtaining the Drug Clinical Trial Approval Notice
- (600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Election of Employee Director
- (600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Implementation of Dividend Distribution for the First Half of 2026
- Announcement on Resolutions of the 25th Meeting of the 9th Board of Directors
Follow Tasly Pharmaceutical into a list and get an email when it puts out news.
Follow Tasly Pharmaceutical